• MJHLS Brand Logo

© 2020 MJH Life Sciences™ and Cure Today. All rights reserved.

Latest Advocacy Group Content

Adaptive Clinical Trial Design Aims to Accelerate Research and Approvals in Pancreatic Cancer

Understanding Disparities in Lung Cancer

An Inside Look at the Cancer Experience Registry and Its Findings on Anxiety in the Patient Population

Cancer Support Community Report Highlights Need for Patient-Provider Discussions to Address Financial Toxicity

View More

Latest Content

Lessons on Pet Cancer From a Cancer Survivor

December 2nd 2020, 5:00pm

By Barbara Tako

Article

A two-time cancer survivor loses her wonderful dog to, of course, cancer and offers advice to avoid some pet cancer pitfalls.

A Look Back at the Beginnings of CAR-T Cell Therapy

December 2nd 2020, 4:00pm

By Jessica Skarzynski

Article

A novel type of immunotherapy known as chimeric antigen receptor, or CAR, T cell therapy is a hot topic in the news and in the lab. But what does this treatment consist of, and how was it developed?

Poteligeo May Result in Antitumor Activity in Adult T-Cell Leukemia/Lymphoma

December 2nd 2020, 2:00pm

By Darlene Dobkowski, MA

Article

Study results also determined that immune system status before treatment may predict outcomes post-treatment.

How Theranostics Differs From the Current Prostate Cancer Treatment Options

December 1st 2020, 10:00pm

By Jessica Skarzynski

Video

While the current field of prostate cancer research is experiencing an era of “warp speed developments,” perhaps the most exciting option on the horizon is theranostics, according to Dr. Phillip J. Koo.

Gavreto Approved by FDA to Treat Thyroid Cancer

December 1st 2020, 8:36pm

By Darlene Dobkowski, MA

Article

The drug has been approved to treat patients with advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer.

Higher Tumor Classification and Grade for Nonmuscle-Invasive Bladder Cancer May Increase Recurrence and Progression Risk Up to Five Years

December 1st 2020, 7:30pm

By Darlene Dobkowski, MA

Article

Predicting risk for recurrence and progression in patients with nonmuscle-invasive bladder cancer may help when discussing management options with clinicians.

FDA Approves First PET Imaging Drug for Prostate-Specific Membrane Antigen Positive Lesions in Prostate Cancer

December 1st 2020, 7:02pm

By Darlene Dobkowski, MA

Article

The radioactive diagnostic agent, Gallium 68 PSMA-11, can detect suspected prostate cancer metastasis or recurrence, providing another imaging option for these patients.

Cancer Burnout and The December Blues

December 1st 2020, 5:00pm

By Khevin Barnes

Article

The holidays are different this year for everyone, but for patients with cancer and cancer survivors, the holidays in 2020 are a unique challenge that presents difficult thoughts to contemplate.

AI May Further Expand Prediction of Immunotherapy Response

December 1st 2020, 4:00pm

By Colleen Moretti

Article

Machine learning may be used to predict disease progression in patients with advanced melanoma.

CURE®’s Top Stories: November 2020

December 1st 2020, 2:00pm

By Jessica Skarzynski

Article

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for November 2020.

x